The patent of "Application of cannabidiol in the preparation of drugs for treating pulmonary hypertension" applied by Deyi Pharmaceutical, a joint venture company established by HYBT-a subsidiary of HYBT and Dezhan Healthcare (000813), officially entered the authorization stage in China.
Previously, the patent has been officially authorized in Japan ("The biopharmaceutical patents of HMI Group have been authorized one after another, and the benefits are continuous"), this patent can fully volatilize cannabidiol CBD in the treatment of pulmonary hypertension, which provides a treatment means and opportunity for patients with pulmonary hypertension, and lays a solid foundation for the preparation of cannabidiol CBD for the treatment of pulmonary hypertension promoted by Deyi Pharmaceutical.
Pulmonary hypertension refers to a hemodynamic and pathophysiological state in which the pulmonary artery pressure rises above a certain threshold, which can lead to right heart failure. It can be an independent disease, a complication or a syndrome. In China, only 25% of patients with pulmonary hypertension are treated with targeted drugs, 56% with other drugs, and 19% with no drugs. An important difference between pulmonary hypertension and other rare diseases or malignant diseases is that patients will have a bright life and future as long as adequate treatment guarantee is provided. However, targeted drugs are expensive, and the monthly drug cost of several thousand dollars brings a heavy economic burden to patients and families. Most patients can't persist in treatment for a long time, and even become poor due to illness.
Therefore, a safe, effective and beneficial new drug has become a rigid demand and urgent need for the treatment of pulmonary hypertension in China. For a long time, Deyi Pharmaceutical independently researched and developed the application of cannabidiol CBD in the treatment of pulmonary hypertension. The authorization of its international patent has taken an important step for Chinese pharmaceutical companies from "imitation" to "original research". At the same time, it has provided a cure possibility for the global treatment of pulmonary hypertension.
HMI Group is the pioneer of China's industrial hemp industry, which is forward-looking and strategic in the layout of intellectual property rights. At present, HMI Group has applied for 181 patents, including 48 overseas applications, 101 domestic invention patents, 21 domestic utility model patents and 10 design patents.
HMI Group has always been based on the protection of intellectual property rights, taking the formation of independent intellectual property rights as the core of its industry. It has spared no effort in the direction of industrial cannabis biopharmaceuticals, constantly trying and exploring, striving to tap the positive ecological role that cannabidiol CBD can play in the cause of great human health, persisting in the historical mission of Industrial hemp industry, broadening its horizons for the global cause of great health, and undertaking future opportunities and challenges.
- ［News］HYBT Water-Soluble CBD
- ［News］Hot ! HMI Group Won Two More PCT International Patents for Biopharmaceuticals.
- ［News］Significant: Hemp Bio-Pharmacy Patent of HMI Group was Officially Authorized in China.
- ［News］Tan Xin, Chairman of HMI Group: The Investment in Industrial Hemp Follows the "Cocoon Breaking Investment Rule", and "Industrial Hemp+"May be the Benchmark of "Internet Plus" | Industrial Hemp Online Live Broadcast Summit.
- ［News］Cheng Lianyuan, Member of the Standing Committee of Yunnan Provincial Party Committee and Secretary of Kunming Municipal Party Committee, and His Party Visited HMI Group.
- ［News］Strong Alliance: HMI Group and Tsinghua University Cross-Strait Development Research Institute have Reached Strategic Cooperation.